NCT03832634 is a NA clinical trial of Fetal Genome Profiling. in Fetal Growth Retardation, sponsored by Weill Medical College of Cornell University.

Who is sponsoring NCT03832634?

NCT03832634 is sponsored by Weill Medical College of Cornell University.

What drugs are being tested in NCT03832634?

Interventions in NCT03832634: Fetal Genome Profiling..

What condition does NCT03832634 study?

NCT03832634 studies Fetal Growth Retardation.

Is NCT03832634 still recruiting?

NCT03832634 is currently terminated. Last updated 3 August 2023.

Last reviewed 2023-08-03 · How we verify

NCT03832634

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Fetal Genome Profiling Via Trophoblast Cells

Terminated NA Last updated 3 August 2023

What this trial tests

NA trial testing Fetal Genome Profiling. in Fetal Growth Retardation in 1 participant. Terminated before completion.

Timeline

2 July 2020

Primary endpoint
14 February 2021

2 February 2023

Quick facts

Lead sponsor	Weill Medical College of Cornell University
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	1
Start date	2 July 2020
Primary completion	14 February 2021
Estimated completion	2 February 2023
Sites	1 location across United States

Drugs / interventions tested

Fetal Genome Profiling.

Conditions studied

Fetal Growth Retardation — all drugs for Fetal Growth Retardation →

Sponsor

Weill Medical College of Cornell University

Who can join

Adults 18 to 45, female only, with Fetal Growth Retardation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study is to utilize trophoblast cells accumulating in the endocervical canal at the beginning of pregnancy for non-invasive prenatal testing. If we are able to validate that trophoblast cells obtained at an early gestational age can be reliably used for prenatal testing, there is great potential to improve early pregnancy management and counseling options for potential parents. The target population will be all women between the age of 18-45 undergoing care at the Center for Reproductive Medicine (CRM) in order to achieve a pregnancy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Fetal Growth Retardation

Currently open trials in the same condition.

NCT06952777 — Validation of Sensors for Long-term Non-Invasive Fetal Monitoring · NA · recruiting
NCT06405360 — DEUX OEUFs: Cracking the Potential of Eggs to Improve Child Growth and Development · NA · active not recruiting
NCT06096805 — Prediction of Placental Fetal Growth Restriction in High Risk Population (PoPFGR) · recruiting
NCT06215690 — Evaluation of Anterior Middle Brain Structures With Cerebrovascular Flow in Fetuses With Fetal Growth Restriction · active not recruiting
NCT06416995 — Serum Vasohibin, Cardiotrophin, Endocan & Perinatal Outcomes · recruiting

Other Weill Medical College of Cornell University trials

Trials by the same sponsor.

NCT07485712 — Center for Research and Education on Aging and Technology Enhancement - CREATE V - Project 2 · NA · not yet recruiting
NCT05811338 — Center for Research and Education on Aging and Technology Enhancement - CREATE V - Project 1 · NA · not yet recruiting
NCT06118983 — Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF) · NA · recruiting
NCT06818734 — Implementation of a Clinical Decision Support Tool for Postpartum Depression · NA · not yet recruiting
NCT07485725 — Center for Research and Education on Aging and Technology Enhancement - CREATE V - Project 3 · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03832634 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Weill Medical College of Cornell University
Last refreshed: 3 August 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03832634.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing